HTBX Heat Biologics Inc

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.

$6.26
As of 09/16/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/24/2013
Outstanding shares:  25,397,376
Average volume:  352,013
Market cap:   $155,431,941
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    42237K409
ISIN:        US42237K4094
Sedol:      BN4GB34
Valuation   (See tab for details)
PE ratio:   -5.41
PB ratio:   1.20
PS ratio:   63.41
Return on equity:   -22.52%
Net income %:   -1,198.61%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy